Peptide and compounding law · Updated
Is PT-141 legal?
PT-141 is another name for bremelanotide, the active ingredient of Vyleesi, which the FDA approved on June 21, 2019 "for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)", as its label defines that condition. Vyleesi is a prescription drug, and the FDA says providers "generally may prescribe" an approved drug for an unapproved use when they judge it medically appropriate. In our reading, a 503A pharmacy may compound from bremelanotide for an identified patient as a component of an approved drug (if no USP or NF monograph exists, from a registered manufacturer, with a certificate of analysis), but not regularly or in inordinate amounts as a copy of Vyleesi. A 2020 FDA letter on a 2018 inspection, before approval, said otherwise; we found no later FDA statement. Research-market PT-141 is, in the FDA's August 24, 2026 warning letters, an unapproved new drug.
| Date | What happened | Source |
|---|---|---|
| June 21, 2019 | The FDA approves Vyleesi (bremelanotide) injection, NDA 210557, a "Type 1 - New Molecular Entity" | Drugs@FDA; approval letter; 85 FR 51448 |
| July 29, 2019 | FDA warning letter: a Florida pharmacy's injectable bremelanotide "differed from and exceeded the labeled amount", so it was "adulterated under section 501(c)" | FDA warning letter |
| April 1, 2020 | FDA warning letter to a Kentucky compounding firm, on an inspection "From August 20, 2018, to October 24, 2018" (before Vyleesi's approval), lists "Bremelanotide (PT-141)" among bulk drug substances that "are not a component of an FDA-approved human drug" | FDA warning letter |
| August 24, 2026 | FDA warning letters to five online sellers, in North Carolina, Florida, Arizona and Texas, name PT-141 among unapproved new drugs | Cornelius, NC seller; Dallas, TX seller |
| October 22, 2026 | The FDA approves a labeling supplement updating "Section 8, Use in Specific Populations"; the label reads "Revised: 10/2026" | Supplement letter; label |
| Channel | Status | Rule |
|---|---|---|
| Vyleesi, on a prescription | FDA-approved for the indication on its label; off label, the FDA says providers "generally may prescribe" an approved drug "when they judge that it is medically appropriate" | Label; FDA on off-label use |
| 503A pharmacy, identified patient, not a copy of Vyleesi | Eligible as a component of an approved drug (our reading) if no USP or NF monograph exists, from a registered manufacturer, with "valid certificates of analysis" and every other 503A condition met; a 2020 FDA letter on a 2018 inspection said otherwise | 21 U.S.C. 353a(b)(1)(A), (b)(2); FDA guidance; 2020 letter |
| 503A pharmacy, essentially a copy of Vyleesi, no documented difference | Not "regularly or in inordinate amounts"; FDA policy: no action at "four or fewer prescriptions" for it "in a calendar month" | 21 U.S.C. 353a(b)(1)(D); FDA guidance |
| 503B outsourcing facility, from bulk | No route (our reading): not on the 503B bulks list (May 16, 2024) or the drug shortage list (November 17, 2026) | 21 U.S.C. 353b(a)(2) |
| FDA category lists and "nominated but withdrawn" table | Not listed (503A list May 14, 2026; 503B list March 21, 2025; safety-risk page April 22, 2026) | 503A list; 503B list; safety-risk page |
| "Research use only" PT-141 sold online | Unapproved new drugs in the FDA's August 24, 2026 letters: "No approved applications ... are in effect for these products" | FDA warning letter |
What PT-141 is, in the FDA's words
The Vyleesi label describes "bremelanotide, a melanocortin receptor agonist for subcutaneous administration via an autoinjector", and its Limitations of Use state: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men" and "VYLEESI is not indicated to enhance sexual performance." (label, revised 10/2026).
Drugs@FDA lists NDA 210557 as Vyleesi, active ingredient "BREMELANOTIDE ACETATE", for subcutaneous use, marketing status "Prescription" (Drugs@FDA), and the FDA's openFDA Drugs@FDA data, updated November 16, 2026, shows no other bremelanotide application (openFDA). Melanotan II has its own entry on the FDA's safety-risk page, in its "nominated but withdrawn" table; neither "bremelanotide" nor "PT-141" appears on that page.
Prescribing Vyleesi, on label and off label
The FDA's position is that "once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient" (FDA, current as of February 5, 2018).
In our reading, off-label prescribing concerns the approved product: it does not turn a compounded or research-market PT-141 into an approved drug, and a clinic's marketing should not contradict the label's "not indicated" statements.
Compounding from bremelanotide under section 503A
Section 503A sets an order for bulk ingredients (21 U.S.C. 353a(b)(1)(A); FDA 503A page, May 14, 2026). The ingredient must "comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding"; "if such a monograph does not exist", it may be one of the "drug substances that are components of drugs approved by the Secretary"; failing both, it must be on the 503A bulks list. Every bulk ingredient must also be "manufactured by an establishment that is registered under section 360" and "accompanied by valid certificates of analysis for each bulk drug substance". Bremelanotide is Vyleesi's active ingredient, so in our reading it has the approved-component route if no USP or NF monograph exists, and must meet the monograph if one does.
Two cautions. First, Drugs@FDA names the approved ingredient "BREMELANOTIDE ACETATE", and the FDA has said semaglutide salts, "including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs" (FDA, October 1, 2026). In our reading, a pharmacy should be able to show its bulk bremelanotide is Vyleesi's active ingredient; we found no FDA statement on bremelanotide salts. Second, an FDA warning letter dated April 1, 2020, after Vyleesi's approval, on an inspection "From August 20, 2018, to October 24, 2018", before it, lists "Bremelanotide (PT-141)" among bulk drug substances that "are not the subject of an applicable USP or NF monograph, are not a component of an FDA-approved human drug, and do not appear on the 503A bulks list" (FDA). The letter does not mention Vyleesi. In our reading, it describes the firm's compounding during the 2018 inspection, before approval; the FDA has not said so, and we found no other FDA statement on whether bremelanotide qualifies under section 503A.
In North Carolina, a pharmacy "may dispense a compounded drug preparation to a patient only pursuant to a prescription that is valid and complies with all requirements of the law", and "Compounded drug preparations shall not be offered to other entities for resale" (21 NCAC 46 .2801).
When compounded PT-141 is "essentially a copy" of Vyleesi
Section 503A bars compounding "regularly or in inordinate amounts" any drugs that are "essentially copies of a commercially available drug product" (21 U.S.C. 353a(b)(1)(D)). Vyleesi's Drugs@FDA marketing status is "Prescription" and it was not on the drug shortage list on November 17, 2026, so in our reading it is commercially available. The general test is in Compounded tirzepatide and semaglutide.
The FDA's 2018 guidance says that "In general, FDA does not intend to consider" a compounded drug a copy when the two "have different routes of administration", but treats it as "essentially a copy" when it has the same ingredient, a strength within 10% or easily substitutable, and a route by which the approved drug "can be used (regardless of how it is labeled)" (FDA guidance, January 2018). In our reading, a compounded injection near Vyleesi's strength is a copy unless the prescriber documents a significant difference for the patient, and "Other factors, such as a lower price, are not sufficient".
No 503B route, and no place on the FDA's peptide lists
An outsourcing facility may compound from bulk only if the substance is on the 503B bulks list, the list of substances "for which there is a clinical need", or the drug is on the shortage list (21 U.S.C. 353b(a)(2)). Unlike section 503A, it has no route for components of approved drugs. The 503B list has five substances, none of them bremelanotide, and the drug shortage database did not list bremelanotide or Vyleesi on November 17, 2026. In our reading, that leaves no 503B source of compounded bremelanotide for office stock; see 503A vs 503B.
Bremelanotide is on none of the FDA's interim category lists or its "nominated but withdrawn" table (how those lists work).
"Research use only" PT-141, nasal sprays and advertising
On August 24, 2026 the FDA warned five online sellers that listed PT-141. Its letter to a Cornelius, North Carolina seller says that despite labeling "for laboratory, research, and analytical use", "evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA). All five say: "No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products." In our reading, Vyleesi's approval covers Vyleesi, not another seller's bremelanotide. See Research-use-only peptides.
No nasal bremelanotide product is FDA-approved, and we found no FDA document on nasal PT-141. In our reading, a nasal spray sold to consumers stands where the products in those letters stand, while a 503A nasal preparation on a valid prescription is generally not a copy of Vyleesi under the guidance's route rule, but rests on the 503A reading above and is not FDA-approved.
A compounded drug is misbranded "If the advertising or promotion of a compounded drug is false or misleading in any particular" (21 U.S.C. 352(bb)). Reminding telehealth companies not to market compounded GLP-1 drugs "with false or misleading claims", the FDA lists "describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA" (FDA, June 15, 2026), and the FTC says health claims for drugs "require substantiation in the form of competent and reliable scientific evidence" (FTC). In our reading, calling compounded PT-141 "generic Vyleesi" or "FDA-approved", or promoting it for uses the label says Vyleesi is "not indicated" for, raises both problems; see Advertising peptides and compounded drugs.
Common questions
Is PT-141 FDA-approved?
Vyleesi (bremelanotide) has been FDA-approved since June 21, 2019 for the indication on its label. A "PT-141" product that is not Vyleesi is not: compounded drugs are not FDA-approved, and the FDA's August 2026 letters say no approved application is in effect for research-market PT-141.
Can a doctor prescribe PT-141 off-label?
A prescriber may prescribe Vyleesi, and the FDA says providers "generally may prescribe" an approved drug for an unapproved use when they judge it medically appropriate. The label says Vyleesi is not indicated for HSDD in postmenopausal women or in men, or to enhance sexual performance. In our reading, that covers Vyleesi only.
Can a compounding pharmacy make PT-141?
In our reading, a 503A pharmacy may, for an identified patient, because bremelanotide is a component of an FDA-approved drug: if no USP or NF monograph exists, from a registered manufacturer with a certificate of analysis, and within the limit on copies of Vyleesi. A 2020 FDA letter on a 2018 inspection said otherwise; we found no later FDA statement. A 503B outsourcing facility has no route from bulk (our reading).
Is PT-141 nasal spray legal?
No nasal bremelanotide is FDA-approved, and we found no FDA document on nasal PT-141. In our reading, a 503A pharmacy may compound one on a valid prescription, since a different route is generally not a copy under the FDA's guidance; sold to consumers otherwise, it is an unapproved new drug.
Is it legal to sell PT-141 online as a research peptide?
Not as a drug for human use, in the FDA's view. In August 2026 it told five sellers that their PT-141 products were unapproved new drugs; its letter to the North Carolina seller judged intended use from the website, not the research label.
Is PT-141 a controlled substance?
Not federally, as of November 17, 2026: bremelanotide does not appear in the Code of Federal Regulations, including the DEA schedules in 21 CFR part 1308. State schedules are separate.
Update log
- November 17, 2026. Published. Read at the source November 17, 2026: the Vyleesi label (revised 10/2026), Drugs@FDA, openFDA's Drugs@FDA data (updated November 16, 2026) and the 2019 and 2026 FDA letters for NDA 210557, 85 FR 51448, the FDA's off-label page, 21 U.S.C. 352, 353a and 353b, 21 CFR part 1308, the FDA's 503A page and copies guidance, the 503A (May 14, 2026) and 503B (March 21, 2025) category lists, the safety-risk page (April 22, 2026), the 503B bulks list, the drug shortage database, the FDA's GLP-1 and telehealth pages, the FTC's guidance, 21 NCAC 46 .2801, and seven FDA warning letters naming bremelanotide or PT-141. Each claim was checked again at the source by a second reviewer the same day. WADA's list could not be read.
Sources
- FDA, Vyleesi (bremelanotide injection) prescribing information, revised 10/2026 (NDA 210557/S-005)
- FDA, Drugs@FDA, NDA 210557 (Vyleesi)
- FDA, openFDA Drugs@FDA data, active ingredient bremelanotide (last updated November 16, 2026)
- FDA, NDA 210557 approval letter (approval action June 21, 2019)
- FDA, NDA 210557/S-005 supplement approval letter (October 22, 2026)
- FDA, Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI, 85 FR 51448 (Aug. 20, 2020)
- FDA, Understanding Unapproved Use of Approved Drugs "Off Label" (current as of February 5, 2018)
- 21 U.S.C. 353a (section 503A)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A (current as of May 14, 2026)
- FDA, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (guidance, January 2018)
- 21 U.S.C. 353b (section 503B)
- FDA, 503B Bulk Drug Substances List (current as of May 16, 2024)
- FDA Drug Shortages database (checked November 17, 2026)
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list, updated May 14, 2026)
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list, updated March 21, 2025)
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of April 22, 2026)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026)
- FDA warning letter, Promise Pharmacy LLC, Palm Harbor, FL (July 29, 2019)
- FDA warning letter, Tailor Made Compounding LLC, Nicholasville, KY (April 1, 2020)
- FDA warning letter, NuScience Peptides LLC, Cornelius, NC (August 24, 2026)
- FDA warning letter, Royal Peptides LLC, Boynton Beach, FL (August 24, 2026)
- FDA warning letter, Peak Performance Peptides, Phoenix, AZ (August 24, 2026)
- FDA warning letter, Peptide Partners LLC, Sarasota, FL (August 24, 2026)
- FDA warning letter, TXP Innovations LLC dba Tex Peptides, Dallas, TX (August 24, 2026)
- 21 U.S.C. 352 (misbranding, including (bb))
- FDA, To Telehealth Companies: What to Know When Promoting Compounded Drugs (current as of June 15, 2026)
- FTC, Health Products Compliance Guidance
- 21 CFR part 1308 (DEA schedules of controlled substances)
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
Related
Adding PT-141 or Vyleesi to a clinic or telehealth program?
DPS Law advises clinics, telehealth companies and pharmacies on federal and North Carolina prescribing, compounding and marketing rules. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state. Our attorney is licensed in North Carolina only.